12:00 AM
Sep 22, 2008
 |  BC Week In Review  |  Company News  |  Other News

Cytokinetics cancer, cardiovascular news

Cytokinetics restructured and reduced headcount by 45 (29%) to 111. The cuts occurred in G&A and early cancer research. Cytokinetics will discontinue its early stage cancer research program to focus on its preclinical muscle biology programs and its clinical drug candidates. The company's lead candidate is CK-1827452, a cardiac myosin activator in Phase IIa testing to treat heart failure. Cytokinetics said by year end it will submit a data package to Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.), which has an option to license worldwide rights to the compound....

Read the full 450 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >